Are there really 44 people "WAITING" for the May clinic results expected near year end?
Regardless of clinical results the guys at Mayo will "KNOW" in advance if GERON is going to zero with bad news or $20 with an ongoing winning chemical product. Amazing given all the patent work done over many years that this is now a one horse option. Disappointed shareholder!
From a shareholder perspective it seems execs have finally given up the dilution trend and now are at least conserving funds to apply to winning concepts. The worst example of the opposite was Okarma building a national network of hospitals capable of doing complex vertebrae surgery while there were only a handful of patients. One hosptial to prove his point would have been enough IMHO.
Hope you are right. In the process, however, he may have killed the potential for unknown fronts shoulod Geron survive as a single entity. It is getting clearer that Scarlett-Huh and company is getting ready to sell the company to or merge with a big pharma which has a much wider sales network. What price the pharma will buy it for? Well, that would now depend on the potential global market for Imetelstat's MF application. Any idea how big is it? Whatever that is, the pharma is going to offer, I would say, no more than half the anticipated average annual revenue times 3 to 5 (i.e., 3 to 5-year duration of patent). My opinion is that we would be lucky if it exceeds $5 per share!!